Cristovam Scapulatempo Neto

Improving Patient Access to Precision Medicine: Developing & Delivering a CDx Solution Globally Using the Liquid Biopsy Solution MSK-ACCESS® Powered with SOPHiA DDM™

In this engager, we demonstrate how MSK-ACCESS® powered with SOPHiA DDM™ is being used to deliver liquid biopsy results to patients globally. We will also discuss how this assay has served as the foundation for a groundbreaking industry collaboration which has resulted in the rethinking of current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine.

• Hear from laboratories and renowned experts who have implemented the liquid biopsy solution, MSK-ACCESS® powered with SOPHiA DDM™, and are currently offering it to their patients and using it in partnerships with pharma companies
• Discover SOPHiA GENETICS’ and Myriad Genetics’ first-of-its-kind CDx partnership model to unlock scale, regulatory compliance, and access to precision diagnostics and therapies, and how this model is being used to gain greater efficiency and to improve the timeliness of commercialization